Global Endometriosis Market Outlook to 2027
Endometriosis is generally a painful condition in which the endometrial cells, which are generally found within the uterus, are present in the body's other areas. Endometriosis affects between 6% and 10% of women of reproductive age globally. The global market for endometriosis is driven by the increasing female population worldwide, intensifying expenditures on public health programs for females, and the increasing global health care expenditures. One of the most significant factors for the market growth is the increasing infertility rate among women globally. However, the lack of awareness about the preventive measures and cause of disease, drug progress challenge in developing countries, and high cost of drugs is likely to hinder the market growth.
The global health spending continues to rise as it was USD 8.45 trillion in 2019 and is anticipated to reach USD 10 trillion by 2022. The United States spends twice the amount as other countries do on health care and having spending of about USD 11,000 per capita. The healthcare sector is made up of multiple branches that contain veterinary healthcare, pharmaceutical drugs, and the medical equipment industry, and many other sectors are connected to form the massive healthcare sector. The success of the healthcare sector mainly depends on the government as to how they plan to take steps for the effectiveness and prosperity of the sector. According to World Health Organization, In 2019, 75% of the healthcare spending was from the American and European regions. The west pacific countries accounted for about 19% of the global spending, whereas Asian and African regions accounted for 2% and 1% of the global spending, respectively. It is observed that health spending is greater in high-income countries whereas lowest in low-income countries.
The United States has made funding of USD 1.4 billion in FY2020 towards women and family health, many of which are focused on maternal and child health, which includes immunization activities, family planning, and reproductive health and nutrition. In OECD countries, health care spending on women accounts for 56% of the total expenditure, with the highest spending on mental health followed by genitourinary diseases like endometriosis, chronic renal failure, Benign Prostatic Hyperplasia (BPH), and many more. According to OECD, in the Czech Republic, Netherlands, Korea, more than 56% of the total healthcare expenditure was consumed by the female population. Since most of the health spending is skewed towards women, men account for a higher proportion of hospitals' spending. In Australia, the average cost for women who have endometriosis both personally and for society is around AUD 30,000, and most of the costs are not from medications and doctor's visits but from the inability of women to work. Only one-fifth of the cost was in the health care sector, and the rest of the bulk cost was lost due to lost productivity. If one in ten women of the working-age has endometriosis, Australia's economic burden is likely to be AUD 9.7 billion every year for endometriosis alone.
The increasing common health risks and the increasing health expenditure across the globe and mainly towards women health care services is likely to drive the global endometriosis market. Although 2020 being a challenging year for the retail sector due to COVID-19, the retail e-commerce sales amounted to USD 4.3 trillion globally and are anticipated to grow to USD 5.4 trillion by 2022. As the world’s biggest exporter, China is also the world’s top e-commerce market, with total online sales around the USD 2 trillion mark in 2019. Together with the United States, these two global economies are responsible for over USD 2.5 trillion worth of online sales, which make up more than 70% of the total revenue generated worldwide. According to, UNCTAD estimates that 1.58 billion people globally aged 15 and older made purchases online in 2019, which is 9% higher than in 2018. While the bulk of online shoppers mainly bought from domestic suppliers, around 350 million online shoppers made cross-border purchases in 2019. The share of cross-border online shoppers rose from 23% in 2018 to 30% in 2019. In, European Union, many countries allow sales of non-prescriptive drugs via e-commerce. In 2020 Germany’s e-pharmacy served 15% of the needs of the country’s consumer health care market. Czech Republic, Slovakia served around 10% of the health care market. Czech and Slovak consumers most often purchase online products related to vitamins, minerals, and nutritional supplements, pain relief, beauty products, but also for cough & cold and respiratory products. These categories represent almost 50% of all sales in Czech e-Pharmacies. Around 70% of the customer base in these countries are women and mainly into the purchase of generic pain relief products like NSAIDs and vitamins.
The United States health care spending grew to 4.6% in 2019, reaching USD 3.8 trillion. As a share of the United States GDP, health spending accounted for 17.7%. During the COVID-19 pandemic and the lockdowns, pharmacy and drug store sales amounted to about USD 297 billion in the United States in 2020. Non-prescription medicines accounted for over USD 32 billion in sales during the same year. Hospitals are the most important cornerstones of every modern healthcare system. Despite this, the total number of hospitals in the United States has constantly decreased over the past few decades. In 2019, most of the hospitals in the United States were non-profit facilities, while the rest were divided in nearly equal parts into for-profit or state/local government hospitals. The number of patient admissions with a primary diagnosis for endometriosis decreased by 76.8% from 2010 to 2019. The number of patients admissions decreased over a decade due to surgical complications and the increasing hospital charges. The United States procured around USD 2.4 billion NSAIDs in 2020 in terms of revenue. The United States' increased usage was due to increasing research activities, increasing health issues like arthritis, endometriosis, migraine, etc.
Also, the study comprehensively analyzes endometriosis by segments based on drug types, By surgery types, by end-user and, by Geography (Asia Pacific, North America, Europe, South America, and Middle-East and Africa). The report examines the market drivers and restraints, along with the impact of Covid-19 are influencing the market growth in detail. The study covers & includes emerging market trends, market estimates, market developments, market opportunities, endometriosis market size, market analysis, market revenue, market dynamics, and challenges in the industry. This report also covers extensively researched competitive landscape sections with profiles of major companies, including their market share/rankings and projects.
The global health spending continues to rise as it was USD 8.45 trillion in 2019 and is anticipated to reach USD 10 trillion by 2022. The United States spends twice the amount as other countries do on health care and having spending of about USD 11,000 per capita. The healthcare sector is made up of multiple branches that contain veterinary healthcare, pharmaceutical drugs, and the medical equipment industry, and many other sectors are connected to form the massive healthcare sector. The success of the healthcare sector mainly depends on the government as to how they plan to take steps for the effectiveness and prosperity of the sector. According to World Health Organization, In 2019, 75% of the healthcare spending was from the American and European regions. The west pacific countries accounted for about 19% of the global spending, whereas Asian and African regions accounted for 2% and 1% of the global spending, respectively. It is observed that health spending is greater in high-income countries whereas lowest in low-income countries.
The United States has made funding of USD 1.4 billion in FY2020 towards women and family health, many of which are focused on maternal and child health, which includes immunization activities, family planning, and reproductive health and nutrition. In OECD countries, health care spending on women accounts for 56% of the total expenditure, with the highest spending on mental health followed by genitourinary diseases like endometriosis, chronic renal failure, Benign Prostatic Hyperplasia (BPH), and many more. According to OECD, in the Czech Republic, Netherlands, Korea, more than 56% of the total healthcare expenditure was consumed by the female population. Since most of the health spending is skewed towards women, men account for a higher proportion of hospitals' spending. In Australia, the average cost for women who have endometriosis both personally and for society is around AUD 30,000, and most of the costs are not from medications and doctor's visits but from the inability of women to work. Only one-fifth of the cost was in the health care sector, and the rest of the bulk cost was lost due to lost productivity. If one in ten women of the working-age has endometriosis, Australia's economic burden is likely to be AUD 9.7 billion every year for endometriosis alone.
The increasing common health risks and the increasing health expenditure across the globe and mainly towards women health care services is likely to drive the global endometriosis market. Although 2020 being a challenging year for the retail sector due to COVID-19, the retail e-commerce sales amounted to USD 4.3 trillion globally and are anticipated to grow to USD 5.4 trillion by 2022. As the world’s biggest exporter, China is also the world’s top e-commerce market, with total online sales around the USD 2 trillion mark in 2019. Together with the United States, these two global economies are responsible for over USD 2.5 trillion worth of online sales, which make up more than 70% of the total revenue generated worldwide. According to, UNCTAD estimates that 1.58 billion people globally aged 15 and older made purchases online in 2019, which is 9% higher than in 2018. While the bulk of online shoppers mainly bought from domestic suppliers, around 350 million online shoppers made cross-border purchases in 2019. The share of cross-border online shoppers rose from 23% in 2018 to 30% in 2019. In, European Union, many countries allow sales of non-prescriptive drugs via e-commerce. In 2020 Germany’s e-pharmacy served 15% of the needs of the country’s consumer health care market. Czech Republic, Slovakia served around 10% of the health care market. Czech and Slovak consumers most often purchase online products related to vitamins, minerals, and nutritional supplements, pain relief, beauty products, but also for cough & cold and respiratory products. These categories represent almost 50% of all sales in Czech e-Pharmacies. Around 70% of the customer base in these countries are women and mainly into the purchase of generic pain relief products like NSAIDs and vitamins.
The United States health care spending grew to 4.6% in 2019, reaching USD 3.8 trillion. As a share of the United States GDP, health spending accounted for 17.7%. During the COVID-19 pandemic and the lockdowns, pharmacy and drug store sales amounted to about USD 297 billion in the United States in 2020. Non-prescription medicines accounted for over USD 32 billion in sales during the same year. Hospitals are the most important cornerstones of every modern healthcare system. Despite this, the total number of hospitals in the United States has constantly decreased over the past few decades. In 2019, most of the hospitals in the United States were non-profit facilities, while the rest were divided in nearly equal parts into for-profit or state/local government hospitals. The number of patient admissions with a primary diagnosis for endometriosis decreased by 76.8% from 2010 to 2019. The number of patients admissions decreased over a decade due to surgical complications and the increasing hospital charges. The United States procured around USD 2.4 billion NSAIDs in 2020 in terms of revenue. The United States' increased usage was due to increasing research activities, increasing health issues like arthritis, endometriosis, migraine, etc.
Also, the study comprehensively analyzes endometriosis by segments based on drug types, By surgery types, by end-user and, by Geography (Asia Pacific, North America, Europe, South America, and Middle-East and Africa). The report examines the market drivers and restraints, along with the impact of Covid-19 are influencing the market growth in detail. The study covers & includes emerging market trends, market estimates, market developments, market opportunities, endometriosis market size, market analysis, market revenue, market dynamics, and challenges in the industry. This report also covers extensively researched competitive landscape sections with profiles of major companies, including their market share/rankings and projects.
1. Executive Summary
2. Research Scope and Methodology
2.1 Aim & Objective of the study
2.2 Market Definition
2.3 Study Information
2.4 General Study Assumptions
2.5 Research Phases
3. Market Analysis
3.1 Introduction
3.2 Market Dynamics
3.2.1 Drivers
3.2.2 Restraints
3.3 Market Trends & Developments
3.4 Market Opportunities
3.5 Regulatory Policies
3.6 Analysis of Covid-19 Impact
4. Industry Analysis
4.1 Supply Chain Analysis
4.2 Porter's Five Forces Analysis
4.2.1 Competition in the Industry
4.2.2 Potential of New Entrants into the Industry
4.2.3 Bargaining Power of Suppliers
4.2.4 Bargaining Power of Consumers
4.2.5 Threat of substitute products
5. Market Segmentation & Forecast
5.1 By Drug Type
5.1.1 Progestin
5.1.2 Oral Contraceptive pills
5.1.3 Non-Steroidal Anti-Inflammatory Drugs (NSAID's)
5.1.4 Gonadotropins Releasing Hormone Agonists
5.2 By Surgery Type
5.2.1 Pelvic Nurse Surgery
5.2.2 Laparotomy
5.2.3 Laparoscopy
5.3 By End User
5.3.1 Hospital
5.3.2 Pharmacies
5.3.3 Drugstores
5.3.4 E-commerce
6. Regional Market Analysis
6.1 North America
6.1.1 United States
6.1.2 Canada
6.1.3 Mexico
6.2 Europe
6.2.1 Germany
6.2.2 United Kingdom
6.2.3 Italy
6.2.4 France
6.2.5 Rest of Europe
6.3 Asia-Pacific
6.3.1 China
6.3.2 India
6.3.3 Japan
6.3.4 South Korea
6.3.5 Rest of Asia-Pacific
6.4 South America
6.4.1 Brazil
6.4.2 Argentina
6.4.3 Rest of South America
6.5 Middle East & Africa
6.5.1 South Africa
6.5.2 Saudi Arabia
6.5.3 Rest of Middle East & Africa
7. Key Company Profiles
7.1 AstraZeneca Plc
7.2 Bayer AG
7.3 Neurocrine Biosciences
7.4 AbbVie, Inc.
7.5 Astellas Pharma, Inc.
7.6 Evestra Inc
7.7 Evatec AG
7.8 Debiopharm Group
7.9 Teva Pharmaceutical Industries Ltd..
7.10 Bio-Rad Laboratories
7.11 ObsEva
7.12 Repros.
7.12 SYNG Pharmaceuticals Inc
7.13 ElexoPharm GmbH
7.14. Chugai Pharmaceutical Co Ltd?€‹
8. Competitive Landscape
8.1 List of Notable Players in the Market
8.2 M&A, JV, and Agreements
8.3 Market Share Analysis
8.4 Strategies of Key Players
9. Conclusions and Recommendations
2. Research Scope and Methodology
2.1 Aim & Objective of the study
2.2 Market Definition
2.3 Study Information
2.4 General Study Assumptions
2.5 Research Phases
3. Market Analysis
3.1 Introduction
3.2 Market Dynamics
3.2.1 Drivers
3.2.2 Restraints
3.3 Market Trends & Developments
3.4 Market Opportunities
3.5 Regulatory Policies
3.6 Analysis of Covid-19 Impact
4. Industry Analysis
4.1 Supply Chain Analysis
4.2 Porter's Five Forces Analysis
4.2.1 Competition in the Industry
4.2.2 Potential of New Entrants into the Industry
4.2.3 Bargaining Power of Suppliers
4.2.4 Bargaining Power of Consumers
4.2.5 Threat of substitute products
5. Market Segmentation & Forecast
5.1 By Drug Type
5.1.1 Progestin
5.1.2 Oral Contraceptive pills
5.1.3 Non-Steroidal Anti-Inflammatory Drugs (NSAID's)
5.1.4 Gonadotropins Releasing Hormone Agonists
5.2 By Surgery Type
5.2.1 Pelvic Nurse Surgery
5.2.2 Laparotomy
5.2.3 Laparoscopy
5.3 By End User
5.3.1 Hospital
5.3.2 Pharmacies
5.3.3 Drugstores
5.3.4 E-commerce
6. Regional Market Analysis
6.1 North America
6.1.1 United States
6.1.2 Canada
6.1.3 Mexico
6.2 Europe
6.2.1 Germany
6.2.2 United Kingdom
6.2.3 Italy
6.2.4 France
6.2.5 Rest of Europe
6.3 Asia-Pacific
6.3.1 China
6.3.2 India
6.3.3 Japan
6.3.4 South Korea
6.3.5 Rest of Asia-Pacific
6.4 South America
6.4.1 Brazil
6.4.2 Argentina
6.4.3 Rest of South America
6.5 Middle East & Africa
6.5.1 South Africa
6.5.2 Saudi Arabia
6.5.3 Rest of Middle East & Africa
7. Key Company Profiles
7.1 AstraZeneca Plc
7.2 Bayer AG
7.3 Neurocrine Biosciences
7.4 AbbVie, Inc.
7.5 Astellas Pharma, Inc.
7.6 Evestra Inc
7.7 Evatec AG
7.8 Debiopharm Group
7.9 Teva Pharmaceutical Industries Ltd..
7.10 Bio-Rad Laboratories
7.11 ObsEva
7.12 Repros.
7.12 SYNG Pharmaceuticals Inc
7.13 ElexoPharm GmbH
7.14. Chugai Pharmaceutical Co Ltd?€‹
*List of companies is not exhaustive
8. Competitive Landscape
8.1 List of Notable Players in the Market
8.2 M&A, JV, and Agreements
8.3 Market Share Analysis
8.4 Strategies of Key Players
9. Conclusions and Recommendations
